Mersana Therapeutics, Inc.
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a MRSN research report →
Companywww.mersana.com
Mersana Therapeutics, Inc. , a clinical stage biopharmaceutical company, develops antibody drug conjugates (ADC) for cancer patients with unmet need. It develops XMT-1592, a Dolasynthen ADC targeting NaPi2b-expressing tumor cells, which is in phase I clinical trial for the treatment of ovarian cancer and NSCLC adenocarcinoma.
- CEO
- Martin H. Huber
- IPO
- 2017
- Employees
- 102
- HQ
- Cambridge, MA, US
Price Chart
Valuation
- Market Cap
- $145.36M
- P/E
- -2.07
- P/S
- 4.38
- P/B
- -2.44
- EV/EBITDA
- -1.38
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 99.14%
- Op Margin
- -203.06%
- Net Margin
- -211.21%
- ROE
- 183.15%
- ROIC
- -310.35%
Growth & Income
- Revenue
- $40.50M · 9.88%
- Net Income
- $-69,192,000 · 59.69%
- EPS
- $-14.12 · 61.80%
- Op Income
- $-73,336,000
- FCF YoY
- 51.78%
Performance & Tape
- 52W High
- $30.39
- 52W Low
- $5.21
- 50D MA
- $22.88
- 200D MA
- $11.99
- Beta
- 0.43
- Avg Volume
- 135.97K
Get TickerSpark's AI analysis on MRSN
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Recent Insider Transactions
| Date | Insider | Type | Shares |
|---|---|---|---|
| Jan 6, 26 | Hack Andrew A. F. | sell | 2,460 |
| Jan 6, 26 | Hack Andrew A. F. | sell | 1,000 |
| Jan 6, 26 | Hack Andrew A. F. | sell | 368 |
| Jan 6, 26 | Hack Andrew A. F. | sell | 1,800 |
| Jan 6, 26 | Hack Andrew A. F. | sell | 2,088 |
| Jan 6, 26 | Hack Andrew A. F. | sell | 734 |
| Jan 6, 26 | Hack Andrew A. F. | sell | 2,200 |
| Jan 6, 26 | Hack Andrew A. F. | sell | 1,002 |
| Jan 6, 26 | Hack Andrew A. F. | sell | 400 |
| Jan 6, 26 | Hack Andrew A. F. | sell | 118 |
Our MRSN Coverage
We haven't published any research on MRSN yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate MRSN Report →